The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders

ISSN： 1746-0441

Source： Expert Opinion on Drug Discovery, Vol.8, Iss.9, 2013-09, pp. : 1165-1179

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vandetanib for the treatment of non-small-cell lung cancer

By Wong Hui-li de Boer Richard H

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 14, 2011-10 ,pp. : 2271-2278

Informa Healthcare

Access to resources Recommend Favorite

Crizotinib: In Locally Advanced or Metastatic Non-Small Cell Lung Cancer

By Curran Monique P.

Drugs, Vol. 72, Iss. 1, 2012-01 ,pp. : 99-107

Adis International

Access to resources Recommend Favorite

Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors

By Danesi Romano Altavilla Giuseppe Giovannetti Elisa Rosell Raffael

Pharmacogenomics, Vol. 10, Iss. 1, 2009-01 ,pp. : 69-80

Future Medicine

Access to resources Recommend Favorite

Axitinib for the treatment of advanced non-small-cell lung cancer

By King Judy W

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 6, 2013-09 ,pp. : 765-773

Informa Healthcare

Access to resources Recommend Favorite

Afatinib for the treatment of advanced non-small-cell lung cancer

By Genova Carlo Rijavec Erika Barletta Giulia Burrafato Giovanni Biello Federica Dal Bello Maria Giovanna Coco Simona Truini Anna Alama Angela Boccardo Francesco Grossi Francesco

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 6, 2014-04 ,pp. : 889-903

Informa Healthcare

Access to resources Recommend Favorite